We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®

TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®

TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®

TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TxCell SA has announced that it has entered into an agreement for the production of clinical batches of Ovasave® with MaSTherCell, a Contract Manufacturing Organization (CMO), based in Belgium.

The contract signed between TxCell and MaSTherCell is a Memorandum of Understanding for the manufacturing by MaSTherCell of clinical batches of TxCell’s Ovasave. These Ovasave batches will be used by TxCell in the ongoing phase IIb trial with the product in refractory Crohn’s disease patients (CATS29 study). The transfer of technology will start immediately. It is intended that first clinical batches could be manufactured as soon as Q2 2016.

In addition, TxCell is currently taking action at its existing pilot Besançon manufacturing unit in order to ensure future compliance with Good Manufacturing Practice (GMP) and recommence full manufacturing activities following a partial, temporary hold at the site.

TxCell will then file to reobtain its GMP certificate as production will resume after the GMP certificate is granted back by the French regulator ANSM.

Ovasave clinical batches for the CATS29 study will be manufactured in parallel by MaSTherCell and TxCell’s own facility. As previously disclosed, the Company expects to deliver top-line data from this study in 2017.

“This strategic relationship with MaSTherCell, a European leader in cellular therapy products manufacturing with a significant track record in production of clinical materials, is very important to TxCell,” said Stéphane Boissel, Chief Executive Officer of TxCell. “We have immediately taken the appropriate actions at our manufacturing site in Besançon and the agreement with MaSTherCell should enable us to rapidly increase the efficiency of our manufacturing. This should both speed up enrollment in CATS29 and accelerate development on other products.”

As part of the Memorandum of Understanding with MaSTherCell, TxCell and MaSTherCell also agree to enter into discussion for the long-term clinical and commercial manufacturing by MaSTherCell of Ovasave and other TxCell products. These discussions will take place in Q4 2015.